Role of endothelin in uteroplacental circulation and fetal vascular function

Current Vascular Pharmacology

Volumn 11, Issue 5, 2013, Pages 594-605

  Paradis, Alexandra ^a   Zhang, Lubo ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelin 1; Fetal circulation; Hypertension; Placenta; Preeclampsia

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM; CYCLO (DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR ANTAGONIST; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IBUPROFEN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE DINITRATE; N (2, 6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHORAMIDON; PROSTAGLANDIN E2; SITAXSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BLOOD VESSEL FUNCTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS OBLITERATION; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; FETUS; FETUS CIRCULATION; FETUS GROWTH; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOREACTIVITY; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC HEART DISEASE; LIVER CELL DAMAGE; LIVER DISEASE; NONHUMAN; PLACENTA CIRCULATION; PREECLAMPSIA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; TROPHOBLAST; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ENDOTHELIN-1; FEMALE; FETUS; HUMANS; PLACENTAL CIRCULATION; PREGNANCY; RECEPTORS, ENDOTHELIN;

EID: 84888106317     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161111311050004     Document Type: Article

References (166)

1. Yanagisawa M, Inoue A, Ishikawa T, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endotheliumderived vasoconstrictor peptide. Proc Natl Acad Sci USA 1988; 85(18): 6964-7. Epub 1988/09/01.
2. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86(8): 2863-7. Epub 1989/04/01.
3. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163): 411-5. Epub 1988/03/31.
4. Kawanabe Y, Nauli SM. Endothelin. Cellular and molecular life sciences: CMLS 2011; 68(2): 195-203. Epub 2010/09/18.
5. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. Journal of the renin-angiotensin-aldosterone system: JRAAS 2002; 3(1): 1-15. Epub 2002/05/02.
6. Kedzierski RM, Yanagisawa M. Endothelin system: the doubleedged sword in health and disease. Ann Rev Pharmacol Toxicol 2001; 41: 851-76. Epub 2001/03/27.
7. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86(8): 485-98. Epub 2008/09/02.
8. Gao Y, Raj JU. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev 2010; 90(4): 1291-335. Epub 2010/10/21.
9. Simard E, Jin D, Takai S, Miyazaki M, Brochu I, D'Orleans-Juste P. Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Therapeut 2009; 328(2): 540-8. Epub 2008/11/07.
10. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85(10): 906-11. Epub 1999/11/13.
11. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP. Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 2003; 93(12): 1249-57. Epub 2003/11/01.
12. Hosoda K, Nakao K, Hiroshi A, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287(1-2): 23-6. Epub 1991/08/05.
13. Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulation 1994; 89(3): 1320-2. Epub 1994/03/01.
14. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990; 348(6303): 730-2. Epub 1990/12/20.
15. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348(6303): 732-5. Epub 1990/12/20.
16. Perreault T, Coceani F. Endothelin in the perinatal circulation. Can J Physiol Pharmacol 2003; 81(6): 644-53. Epub 2003/07/04.
17. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Brit J Pharmacol 1993; 110(2): 777-82. Epub 1993/10/01.
18. Wilkes BM, Susin M, Mento PF. Localization of endothelin-1-like immunoreactivity in human placenta. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 1993; 41(4): 535-41. Epub 1993/04/01.
19. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacological reviews. 1994; 46(3): 325-415. Epub 1994/09/01.
20. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267(23): 16066-8. Epub 1992/08/15.
21. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992; 10(11): 1379-86. Epub 1992/11/01.
22. Kelly JJ, Whitworth JA. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 1999; 26(2): 158-61. Epub 1999/03/05.
23. Goldie RG. Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 1999; 26(2): 145-8. Epub 1999/03/05.
24. Ponicke K, Vogelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998; 97(8): 744-51. Epub 1998/03/14.
25. Zolk O, Quattek J, Sitzler G, et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999; 99(16): 2118-23. Epub 1999/04/27.
26. Barros JS, Bairos VA, Baptista MG, Fagulha JO. Immunocytochemical localization of endothelin-1 in human placenta from normal and preeclamptic pregnancies. Hypertension in pregnancy: official journal of the International Society for the Study of Hypertension in Pregnancy 2001; 20(1): 125-37. Epub 2002/06/05.
27. Ferre F, Mondon F, Mignot TM, et al. Endothelin-1 binding sites and immunoreactivity in the cultured human placental trophoblast: evidence for an autocrine and paracrine role for endothelin-1. J Cardiovasc Pharmacol 1993; 22 (Suppl 8): S214-8. Epub 1993/01/01.
28. Casey ML, Word RA, MacDonald PC. Endothelin-1 gene expression and regulation of endothelin mRNA and protein biosynthesis in avascular human amnion. Potential source of amniotic fluid endothelin. J Biol Chem1991; 266(9): 5762-8. Epub 1991/03/25.
29. Hasegawa M, Sagawa N, Ihara Y, et al. Concentrations of endothelin-1 in human amniotic fluid at various stages of pregnancy. J Cardiovasc Pharmacol 1991; (17 Suppl) 7: S440-2. Epub 1991/01/01.
30. Hasegawa M, Sagawa N, Itoh H, et al. Endothelin receptors in the human amnion, chorion laeve, decidua vera and placenta. Reproduction, fertility, and development. 1995; 7(6): 1585-9. Epub 1995/01/01.
31. Sand AE, Ostlund E, Andersson E, Fried G. Endothelin-induced contractions in placental arteries is mediated by both ETA-and ETB-receptors. Acta Physiol Scand 1998; 163(3): 227-34. Epub 1998/08/26.
32. Ahmad Z, Reznik SE. Immunohistochemical localization of ECE-1 in the human placenta. Placenta 2000; 21(2-3): 226-33. Epub 2000/03/29.
33. Gan XT, Chakrabarti S, Karmazyn M. Increased endothelin-1 and endothelin receptor expression in myocytes of ischemic and reperfused rat hearts and ventricular myocytes exposed to ischemic conditions and its inhibition by nitric oxide generation. Can J Physiol Pharmacol 2003; 81(2): 105-13. Epub 2003/04/25.
34. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox KA. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Brit Heart J 1994; 72(5): 436-41. Epub 1994/11/01.
35. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37(2 Part 2): 485-9. Epub 2001/03/07.
36. Tanbe AF, Khalil RA. Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy. Curr Bioact Comp 2010; 6(1): 60-75. Epub 2010/04/27.
37. Dechanet C, Fort A, Barbero-Camps E, Dechaud H, Richard S, Virsolvy A. Endothelin-dependent vasoconstriction in human uterine artery: application to preeclampsia. PloS one 2011; 6(1): e16540. Epub 2011/02/08.
38. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. American journal of physiology Heart and circulatory physiology. 2008; 294(2): H541-50. Epub 2007/12/07.
39. Roberts JM, Pearson G, Cutler J, Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003; 41(3): 437-45. Epub 2003/03/08.
40. Napolitano M, Miceli F, Calce A, Vacca A, Gulino A, Apa R, et al. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab 2000; 85(6): 2318-23. Epub 2000/06/14.
41. Anderson CM. Preeclampsia: exposing future cardiovascular risk in mothers and their children. Journal of obstetric, gynecologic, and neonatal nursing: JOGNN/NAACOG. 2007; 36(1): 3-8. Epub 2007/01/24.
42. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011; 24(9): 964-9. Epub 2011/06/17.
43. Genbacev O, Joslin R, Damsky CH, Polliotti BM, Fisher SJ. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Investig 1996; 97(2): 540-50. Epub 1996/01/15.
44. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta 2006; 27(9-10): 939-58. Epub 2006/02/24.
45. Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens 2012; 26(4): 236-41. Epub 2011/04/01.
46. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007; 92(7): 2672-9. Epub 2007/04/12.
47. Veas CJ, Aguilera VC, Munoz IJ, et al. Fetal endothelium dysfunction is associated with circulating maternal levels of sEselectin, sVCAM1, and sFlt-1 during pre-eclampsia. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2011; 24(11): 1371-7. Epub 2011/03/09.
48. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ (Clinical Research ed). 2001; 323(7323): 1213-7. Epub 2001/11/24.
49. Mangos GJ. Cardiovascular disease following pre-eclampsia: understanding the mechanisms. J Hypertens 2006; 24(4): 639-41. Epub 2006/03/15.
50. Wilson BJ, Watson MS, Prescott GJ, et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ (Clinical Research ed). 2003; 326(7394): 845. Epub 2003/04/19.
51. Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-term prognosis of hypertension in pregnancy. Hypertension in pregnancy: official journal of the International Society for the Study of Hypertension in Pregnancy 2000; 19(2): 199-209. Epub 2000/07/06.
52. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129, 290 births. Lancet 2001; 357(9273): 2002-6. Epub 2001/07/05.
53. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. New Engl J Med 2001; 344(12): 867-72. Epub 2001/03/22.
54. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ (Clinical research ed) 2005; 331(7521): 877. Epub 2005/09/20.
55. Barker DJ. The developmental origins of chronic adult disease. Acta paediatrica (Oslo, Norway: 1992) Supplement. 2004; 93(446): 26-33. Epub 2005/02/11.
56. Barker DJ. Fetal origins of coronary heart disease. BMJ (Clinical research ed). 1995; 311(6998): 171-4. Epub 1995/07/15.
57. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 2008; 34(6): 957-63. Epub 2008/11/18.
58. Florijn KW, Derkx FH, Visser W, et al. Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S446-8. Epub 1991/01/01.
59. Ihara Y, Sagawa N, Hasegawa M, et al. Concentrations of endothelin-1 in maternal and umbilical cord blood at various stages of pregnancy. J Cardiovasc Pharmacol 1991; 17 Suppl 7: S443-5. Epub 1991/01/01.
60. Wang CN, Chang SD, Peng HH, et al. Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab 2010; 95(3): 1431-41. Epub 2010/01/19.
61. Singh HJ, Rahman A, Larmie ET, Nila A. Endothelin-l in fetoplacental tissues from normotensive pregnant women and women with pre-eclampsia. Acta Obstet Gynecol Scand 2001; 80(2): 99-103. Epub 2001/02/13.
62. Benigni A, Orisio S, Gaspari F, Frusca T, Amuso G, Remuzzi G. Evidence against a pathogenetic role for endothelin in preeclampsia. Brit J Obstet Gynaecol 1992; 99(10): 798-802. Epub 1992/10/01.
63. Ajne G, Wolff K, Fyhrquist F, Carlstrom K, Hemsen-Mortberg A, Nisell H. Endothelin converting enzyme (ECE) activity in normal pregnancy and preeclampsia. Hypertension in pregnancy: official journal of the International Society for the Study of Hypertension in Pregnancy. 2003; 22(3): 215-24. Epub 2003/10/24.
64. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 2001; 276(16): 12645-53. Epub 2001/03/30.
65. Caniggia I, Winter JL. Adriana and Luisa Castellucci Award lecture 2001. Hypoxia inducible factor-1: oxygen regulation of trophoblast differentiation in normal and pre-eclamptic pregnancies--a review. Placenta 2002; 23 Suppl A: S47-57. Epub 2002/04/30.
66. Rajakumar A, Brandon HM, Daftary A, Ness R, Conrad KP. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25(10): 763-9. Epub 2004/09/29.
67. Caniggia I, Mostachfi H, Winter J, et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Investig 2000; 105(5): 577-87. Epub 2000/03/11.
68. Tal R, Shaish A, Barshack I, et al. Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction. Am J Pathol 2010; 177(6): 2950-62. Epub 2010/10/19.
69. Morin FC, 3rd, Egan EA. Pulmonary hemodynamics in fetal lambs during development at normal and increased oxygen tension. J Appl Physiol (Bethesda, Md: 1985). 1992; 73(1): 213-8. Epub 1992/07/01.
70. Ivy DD, Parker TA, Ziegler JW, et al. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Investig 1997; 99(6): 1179-86. Epub 1997/03/15.
71. Rasanen J, Wood DC, Debbs RH, Cohen J, Weiner S, Huhta JC. Reactivity of the human fetal pulmonary circulation to maternal hyperoxygenation increases during the second half of pregnancy: a randomized study. Circulation 1998; 97(3): 257-62. Epub 1998/02/14.
72. Wang Y, Coceani F. Isolated pulmonary resistance vessels from fetal lambs. Contractile behavior and responses to indomethacin and endothelin-1. Circ Res 1992; 71(2): 320-30. Epub 1992/08/01.
73. Hislop A. Developmental biology of the pulmonary circulation. Paediatric respiratory reviews. 2005; 6(1): 35-43. Epub 2005/02/09.
74. Levy M, Maurey C, Chailley-Heu B, Martinovic J, Jaubert F, Israel-Biet D. Developmental changes in endothelial vasoactive and angiogenic growth factors in the human perinatal lung. Pediatr Res 2005; 57(2): 248-53. Epub 2004/12/22.
75. Ivy DD, Kinsella JP, Abman SH. Physiologic characterization of endothelin A and B receptor activity in the ovine fetal pulmonary circulation. J Clin Investig 1994; 93(5): 2141-8. Epub 1994/05/01.
76. Ivy DD, le Cras TD, Parker TA, et al. Developmental changes in endothelin expression and activity in the ovine fetal lung. Am J Physiol Lung Cell Mol Physiol 2000; 278(4): L785-93. Epub 2000/04/06.
77. Ivy DD, Ziegler JW, Dubus MF, Fox JJ, Kinsella JP, Abman SH. Chronic intrauterine pulmonary hypertension alters endothelin receptor activity in the ovine fetal lung. Pediatr Res 1996; 39(3): 435-42. Epub 1996/03/01.
78. Schindler MB, Hislop AA, Haworth SG. Postnatal changes in pulmonary vein responses to endothelin-1 in the normal and chronically hypoxic lung. Am J Physiol Lung Cell Mol Physiol 2007; 292(5): L1273-9. Epub 2007/01/30.
79. Ivy D, Tanzawa K, Abman SH. Ontogeny of endothelin-converting enzyme gene expression and protein content in the ovine fetal lung. Biol Neonate 2002; 81(2): 139-44. Epub 2002/02/15.
80. Levy M, Maurey C, Dinh-Xuan AT, Vouhe P, Israel-Biet D. Developmental expression of vasoactive and growth factors in human lung. Role in pulmonary vascular resistance adaptation at birth. Pediatr Res 2005; 57(5 Pt 2): 21R-5R. Epub 2005/04/09.
81. Endo A, Ayusawa M, Minato M, Takada M, Takahashi S, Harada K. Endogenous nitric oxide and endothelin-1 in persistent pulmonary hypertension of the newborn. Eur J Pediatr 2001; 160(4): 217-22. Epub 2001/04/25.
82. Ivy DD, Le Cras TD, Horan MP, Abman SH. Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension. Am J Physiol 1998; 274(4 Pt 1): L535-41. Epub 1998/05/12.
83. Kumar P, Kazzi NJ, Shankaran S. Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn. Am J Perinatol 1996; 13(6): 335-41. Epub 1996/08/01.
84. Bokenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-de Groot AC. Insights into the pathogenesis and genetic background of patency of the ductus arteriosus. Neonatology 2010; 98(1): 6-17. Epub 2009/12/04.
85. Heymann MA, Rudolph AM. Control of the ductus arteriosus. Physiol Rev 1975; 55(1): 62-78. Epub 1975/01/01.
86. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006; 89(4): 330-5. Epub 2006/06/14.
87. Ivey KN, Sutcliffe D, Richardson J, Clyman RI, Garcia JA, Srivastava D. Transcriptional regulation during development of the ductus arteriosus. Circ Res 2008; 103(4): 388-95. Epub 2008/07/19.
88. Clyman RI, Mauray F, Roman C, Rudolph AM. PGE2 is a more potent vasodilator of the lamb ductus arteriosus than is either PGI2 or 6 keto PGF1alpha. Prostaglandins 1978; 16(2): 259-64. Epub 1978/08/01.
89. Coceani F, Kelsey L, Seidlitz E. The response of the lamb ductus arteriosus to endothelin: developmental changes and influence of light. Life Sci 2002; 71(10): 1209-17. Epub 2002/07/04.
90. Momma K, Nakanishi T, Imamura S. Inhibition of in vivo constriction of fetal ductus arteriosus by endothelin receptor blockade in rats. Pediatr Res 2003; 53(3): 479-85. Epub 2003/02/22.
91. Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ET(A) receptors. Life Sci 2003; 74(2-3): 405-9. Epub 2003/11/11.
92. Coceani F, Liu Y, Seidlitz E, Kelsey L, Kuwaki T, Ackerley C, et al. Endothelin A receptor is necessary for O(2) constriction but not closure of ductus arteriosus. Am J Physiol 1999; 277(4 Pt 2): H1521-31. Epub 1999/10/12.
93. Costa M, Barogi S, Socci ND, et al. Gene expression in ductus arteriosus and aorta: comparison of birth and oxygen effects. Physiol Genomics 2006; 25(2): 250-62. Epub 2006/01/19.
94. Baragatti B, Ciofini E, Scebba F, et al. Cytochrome P-450 3A13 and endothelin jointly mediate ductus arteriosus constriction to oxygen in mice. Am J Physiol Heart Circ Physiol 2011; 300(3): H892-901. Epub 2011/01/05.
95. Agren P, Cogolludo AL, Kessels CG, et al. Ontogeny of chicken ductus arteriosus response to oxygen and vasoconstrictors. American Journal of physiology Regulatory, Integrative and Comparative Physiology 2007; 292(1): R485-96. Epub 2006/08/19.
96. Fineman JR, Takahashi Y, Roman C, Clyman RI. Endothelinreceptor blockade does not alter closure of the ductus arteriosus. Am J Physiol 1998; 275(5 Pt 2): H1620-6. Epub 1998/11/14.
97. Cetin I, Foidart JM, Miozzo M, et al. Fetal growth restriction: a workshop report. Placenta. 2004; 25(8-9): 753-7. Epub 2004/09/29.
98. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365(9461): 785-99. Epub 2005/03/01.
99. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006; 195(1): 40-9. Epub 2006/07/04.
100. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science (New York, NY) 2005; 308(5728): 1592-4. Epub 2005/06/11.
101. Thaete LG, Neerhof MG, Caplan MS. Endothelin receptor A antagonism prevents hypoxia-induced intrauterine growth restriction in the rat. Am J Obstet Gynecol 1997; 176(1 Pt 1): 73-6. Epub 1997/01/01.
102. Nezar MA, el-Baky AM, Soliman OA, Abdel-Hady HA, Hammad AM, Al-Haggar MS. Endothelin-1 and leptin as markers of intrauterine growth restriction. Ind J Pediatr 2009; 76(5): 485-8. Epub 2009/04/25.
103. Li H, Chen SJ, Chen YF, et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. Journal of applied physiology (Bethesda, Md: 1985). 1994; 77(3): 1451-9. Epub 1994/09/01.
104. Thaete LG, Kushner DM, Dewey ER, Neerhof MG. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. Placenta 2005; 26(2-3): 242-50. Epub 2005/02/15.
105. Giannubilo SR, Menegazzi M, Tedeschi E, Bezzeccheri V, Suzuki H, Tranquilli AL. Doppler analysis and placental nitric oxide synthase expression during fetal growth restriction. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2008; 21(9): 617-22. Epub 2008/10/02.
106. Brand M, Kempf H, Paul M, Corvol P, Gasc JM. Expression of endothelins in human cardiogenesis. Journal of molecular medicine (Berlin, Germany) 2002; 80(11): 715-23. Epub 2002/11/19.
107. Chen M, Lin YQ, Xie SL, Wang JF. Mitogen-activated protein kinase in endothelin-1-induced cardiac differentiation of mouse embryonic stem cells. J Cell Biochem 2010; 111(6): 1619-28. Epub 2010/11/06.
108. Patel R, Kos L. Endothelin-1 and Neuregulin-1 convert embryonic cardiomyocytes into cells of the conduction system in the mouse. Developmental dynamics: an official publication of the American Association of Anatomists. 2005; 233(1): 20-8. Epub 2005/03/11.
109. Wharton J, Rutherford RA, Gordon L, et al. Localization of endothelin binding sites and endothelin-like immunoreactivity in human fetal heart. J Cardiovasc Pharmacol 1991; 17 Suppl 7: S378-84. Epub 1991/01/01.
110. Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Investig 2000; 105(10): 1373-82. Epub 2000/05/17.
111. Hauselmann SP, Rosc-Schluter BI, Lorenz V, et al. beta1-Integrin is up-regulated via Rac1-dependent reactive oxygen species as part of the hypertrophic cardiomyocyte response. Free Radic Biol Med 2011; 51(3): 609-18. Epub 2011/05/31.
112. Komati H, Maharsy W, Beauregard J, Hayek S, Nemer M. ZFP260 is an inducer of cardiac hypertrophy and a nuclear mediator of endothelin-1 signaling. J Biol Chem 2011; 286(2): 1508-16. Epub 2010/11/06.
113. Majumdar P, Chen S, George B, Sen S, Karmazyn M, Chakrabarti S. Leptin and endothelin-1 mediated increased extracellular matrix protein production and cardiomyocyte hypertrophy in diabetic heart disease. Diabetes/metabolism research and reviews. 2009; 25(5): 452-63. Epub 2009/04/25.
114. Shimojo N, Jesmin S, Zaedi S, et al. Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 2007; 293(1): H474-81. Epub 2007/03/21.
115. Tamamori M, Ito H, Adachi S, Akimoto H, Marumo F, Hiroe M. Endothelin-3 induces hypertrophy of cardiomyocytes by the endogenous endothelin-1-mediated mechanism. J Clin Investig 1996; 97(2): 366-72. Epub 1996/01/15.
116. Alvarez D, Briassouli P, Clancy RM, et al. A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem 2011; 286(35): 30444-54. Epub 2011/07/07.
117. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27(12): 2130-4. Epub 1993/12/01.
118. Widyantoro B, Emoto N, Nakayama K, et al. Endothelial cellderived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010; 121(22): 2407-18. Epub 2010/05/26.
119. Tong W, Xue Q, Li Y, Zhang L. Maternal hypoxia alters matrix metalloproteinase expression patterns and causes cardiac remodeling in fetal and neonatal rats. Am J Physiol Heart Circ Physiol 2011; 301(5): H2113-21. Epub 2011/08/23.
120. Bae S, Xiao Y, Li G, Casiano CA, Zhang L. Effect of maternal chronic hypoxic exposure during gestation on apoptosis in fetal rat heart. Am J Physiol Heart Circ Physiol 2003; 285(3): H983-90. Epub 2003/05/17.
121. Louey S, Thornburg KL. The prenatal environment and later cardiovascular disease. Early Hum Dev 2005; 81(9): 745-51. Epub 2005/09/03.
122. Li G, Bae S, Zhang L. Effect of prenatal hypoxia on heat stressmediated cardioprotection in adult rat heart. Am J Physiol Heart Circ Physiol 2004; 286(5): H1712-9. Epub 2004/01/13.
123. Xu Y, Williams SJ, O'Brien D, Davidge ST. Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspring. FASEB journal: official publication of the Federation of Am Soc Expe Biol 2006; 20(8): 1251-3. Epub 2006/04/25.
124. Li G, Xiao Y, Estrella JL, Ducsay CA, Gilbert RD, Zhang L. Effect of fetal hypoxia on heart susceptibility to ischemia and reperfusion injury in the adult rat. J Soc Gynecol Investig 2003; 10(5): 265-74. Epub 2003/07/11.
125. Patterson AJ, Chen M, Xue Q, Xiao D, Zhang L. Chronic prenatal hypoxia induces epigenetic programming of PKC{epsilon} gene repression in rat hearts. Circ Res 2010; 107(3): 365-73. Epub 2010/06/12.
126. Xue Q, Dasgupta C, Chen M, Zhang L. Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury. Cardiovasc Res 2011; 89(2): 300-8. Epub 2010/09/28.
127. Xue Q, Zhang L. Prenatal hypoxia causes a sex-dependent increase in heart susceptibility to ischemia and reperfusion injury in adult male offspring: role of protein kinase C epsilon. J Pharmacol Exp Therapeut 2009; 330(2): 624-32. Epub 2009/05/28.
128. Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 2009; 53(15): 1309-17. Epub 2009/04/11.
129. Hedegaard ER, Stankevicius E, Simonsen U, Frobert O. Nonendothelial endothelin counteracts hypoxic vasodilation in porcine large coronary arteries. BMC Physiol 2011; 11(1): 8. Epub 2011/05/18.
130. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998; 16(8): 1081-98. Epub 1998/10/30.
131. Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299(6): H1959-67. Epub 2010/09/21.
132. Hayasaki-Kajiwara Y, Naya N, Shimamura T, Iwasaki T, Nakajima M. Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Brit J Pharmacol 1999; 127(6): 1415-21. Epub 1999/08/24.
133. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Investig 1993; 92(1): 99-104. Epub 1993/07/01.
134. Rautureau Y, Schiffrin EL. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens 2012; 21(2): 128-36. Epub 2012/01/20.
135. George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens 2012; 21(2): 157-62. Epub 2012/01/20.
136. Sabry S, Mondon F, Levy M, Ferre F, Dinh-Xuan AT. Endothelial modulation of vasoconstrictor responses to endothelin-1 in human placental stem villi small arteries. Brit J Pharmacol 1995; 115(6): 1038-42. Epub 1995/07/01.
137. Sheppard SJ, Khalil RA. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disorders Drug Targets 2010; 10(1): 33-52. Epub 2010/01/01.
138. George EM, Granger JP. Mechanisms and potential therapies for preeclampsia. Curr Hypertens Rep 2011; 13(4): 269-75. Epub 2011/04/06.
139. Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development (Cambridge, England). 1998; 125(5): 813-24. Epub 1998/05/09.
140. LaMarca BD, Alexander BT, Gilbert JS, et al. Pathophysiology of hypertension in response to placental ischemia during pregnancy: a central role for endothelin? Gender Med 2008; 5 Suppl A: S133-8. Epub 2008/05/28.
141. Tam Tam KB, George E, Cockrell K, et al. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol 2011; 204(4): 330 e1-4. Epub 2011/04/05.
142. Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011; 7(5): 659-74. Epub 2011/09/08.
143. Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J Immunol (Baltimore, Md: 1950). 2007; 179(6): 3391-5. Epub 2007/09/06.
144. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009; 54(4): 905-9. Epub 2009/08/26.
145. Reslan OM, Khalil RA. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem 2010; 8(4): 204-26. Epub 2010/10/07.
146. Angerio AD. Endothelin-mediated preeclampsia at high altitude. Crit Care Nursing Quart 2000; 23(2): 73-8. Epub 2002/02/21.
147. Nakatsuka M, Takata M, Tada K, et al. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 2002; 21(8): 831-6. Epub 2002/08/08.
148. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S): 62S-7S. Epub 2004/06/15.
149. Venitz J, Zack J, Gillies H, Allard M, Regnault J, Dufton C. Clinical Pharmacokinetics and Drug-Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. J Clin Pharmacol 2011. Epub 2011/12/30.
150. Hamidi SA, Lin RZ, Szema AM, Lyubsky S, Jiang YP, Said SI. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension. Respir Res 2011; 12: 141. Epub 2011/10/28.
151. Agarwal R, Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J 2011; 162(2): 201-13. Epub 2011/08/13.
152. O'Callaghan DS, Savale L, Yaici A, et al. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2011; 12(10): 1585-96. Epub 2011/04/21.
153. Kingman M, Ruggiero R, Torres F. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2009; 10(11): 1847-58. Epub 2009/07/16.
154. Frampton JE. Ambrisentan. American journal of cardiovascular drugs: drugs, devices, and other interventions. 2011; 11(4): 215-26. Epub 2011/06/01.
155. Beghetti M, Galie N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53(9): 733-40. Epub 2009/02/28.
156. Mehta PK, Simpson L, Lee EK, Lyle TA, McConnell ME, Book WM. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects. Texas Heart Institute journal/from the Texas Heart Institute of St Luke's Episcopal Hospital, Texas Children's Hospital. 2008; 35(3): 256-61. Epub 2008/10/23.
157. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008; 327(3): 736-45. Epub 2008/09/11.
158. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Current opinion in investigational drugs (London, England: 2000). 2010; 11(9): 1066-73. Epub 2010/08/24.
159. Oishi P, Datar SA, Fineman JR. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. Expert Opin Pharmacother 2011; 12(12): 1845-64. Epub 2011/05/26.
160. Boniface S, Reynaud-Gaubert M. Endothelin receptor antagonists-their role in pulmonary medicine. Revue des maladies respiratoires. 2011; 28(8): e94-e107. Epub 2011/11/22.
161. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010; 125(5): 1020-30. Epub 2010/04/28.
162. Zanardo V, Vedovato S, Chiozza L, Faggian D, Favaro F, Trevisanuto D. Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion. Am J Perinatol 2008; 25(6): 353-8. Epub 2008/05/30.
163. Seidner SR, Chen YQ, Oprysko PR, Mauray F, Tse MM, Lin E, et al. Combined prostaglandin and nitric oxide inhibition produces anatomic remodeling and closure of the ductus arteriosus in the premature newborn baboon. Pediatr Res 2001; 50(3): 365-73. Epub 2001/08/24.
164. Angerio AD, Kot PA. Closure of the ductus arteriosus--new insights for critical care. Crit Care Nursing Quart 1998; 20(4): 80-5. Epub 1998/03/13.
165. Coceani F, Kelsey L, Seidlitz E. Evidence for an effector role of endothelin in closure of the ductus arteriosus at birth. Can J Physiol Pharmacol 1992; 70(7): 1061-4. Epub 1992/07/01.
166. Barker DJ. Fetal nutrition and cardiovascular disease in later life. Brit Med Bull 1997; 53(1): 96-108. Epub 1997/01/01.